These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 25727451)

  • 1. Harm reduction in U.S. tobacco control: Constructions in textual news media.
    Eversman MH
    Int J Drug Policy; 2015 Jun; 26(6):575-82. PubMed ID: 25727451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. We need to regulate the contents and construction of cigarettes to discourage initiation and facilitate cessation.
    King B
    Tob Control; 2015 Dec; 24(e4):e232. PubMed ID: 26660075
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
    Kozlowski LT
    Am J Prev Med; 2007 Dec; 33(6 Suppl):S379-86. PubMed ID: 18021913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for a nicotine-reduction strategy in the cigarette endgame: Alternative tobacco harm reduction scenarios.
    Kozlowski LT
    Int J Drug Policy; 2015 Jun; 26(6):543-7. PubMed ID: 25795345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No sisyphean task: how the FDA can regulate electronic cigarettes.
    Paradise J
    Yale J Health Policy Law Ethics; 2013; 13(2):326-74. PubMed ID: 24340824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction.
    Kozlowski LT; Abrams DB
    BMC Public Health; 2016 May; 16():432. PubMed ID: 27221096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Content Analysis of US News Stories About E-Cigarettes in 2015.
    Wackowski OA; Giovenco DP; Singh B; Lewis MJ; Steinberg MB; Delnevo CD
    Nicotine Tob Res; 2018 Jul; 20(8):1015-1019. PubMed ID: 29065205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harm reduction policies for tobacco users.
    Gartner C; Hall W
    Int J Drug Policy; 2010 Mar; 21(2):129-30. PubMed ID: 19944582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobacco, nicotine and harm reduction.
    Le Houezec J; McNeill A; Britton J
    Drug Alcohol Rev; 2011 Mar; 30(2):119-23. PubMed ID: 21375611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of product definitions in US e-cigarette laws and regulations.
    Lempert LK; Grana R; Glantz SA
    Tob Control; 2016 Apr; 25(e1):e44-51. PubMed ID: 25512432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smokeless tobacco: the epidemiology and politics of harm.
    Phillips CV; Heavner KK
    Biomarkers; 2009 Jul; 14 Suppl 1():79-84. PubMed ID: 19604065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging nicotine delivery products. Implications for public health.
    Benowitz NL
    Ann Am Thorac Soc; 2014 Feb; 11(2):231-5. PubMed ID: 24575992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a comprehensive policy on nicotine delivery products and harm reduction.
    Solyst J
    Food Drug Law J; 2012; 67(4):393-404, i. PubMed ID: 24640613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is "tobacco harm reduction" possible? Other countries' experiences and perspectives, and how they could inform tobacco control in Japan].
    Katanoda K; Togawa K; Nakamura M
    Nihon Koshu Eisei Zasshi; 2024 Mar; 71(3):141-152. PubMed ID: 38123330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ethics of Tobacco Harm Reduction: An Analysis of E-Cigarette Availability From the Perspectives of Utilitarianism, Bioethics, and Public Health Ethics.
    Thomas R; Parker LS; Shiffman S
    Nicotine Tob Res; 2021 Jan; 23(1):3-8. PubMed ID: 33002156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harm reduction and the medicalisation of tobacco use.
    Rooke C
    Sociol Health Illn; 2013 Mar; 35(3):361-76. PubMed ID: 22670865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology.
    Brandon TH; Goniewicz ML; Hanna NH; Hatsukami DK; Herbst RS; Hobin JA; Ostroff JS; Shields PG; Toll BA; Tyne CA; Viswanath K; Warren GW
    J Clin Oncol; 2015 Mar; 33(8):952-63. PubMed ID: 25572671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes.
    Dunsby J; Bero L
    Tob Control; 2004 Dec; 13(4):362-9. PubMed ID: 15564619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The place for harm reduction and product regulation in UK tobacco control policy.
    Gilmore AB; Britton J; Arnott D; Ashcroft R; Jarvis MJ
    J Public Health (Oxf); 2009 Mar; 31(1):3-10. PubMed ID: 19109341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobacco harm reduction: the need for new products that can compete with cigarettes.
    Fagerström KO; Bridgman K
    Addict Behav; 2014 Mar; 39(3):507-11. PubMed ID: 24290207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.